Thomas J Tucker

List of Publications by Year
in descending order

14	660	858243 12	1181555 14
papers	citations	h-index	g-index

16	16	16	777
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 16770-16800.	2.9	57
2	Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design. Journal of Medicinal Chemistry, 2020, 63, 13796-13824.	2.9	48
3	Novel pH Selective, Highly Lytic Peptides Based on a Chimeric Influenza Hemagglutinin Peptide/Cell Penetrating Peptide Motif. Molecules, 2019, 24, 2079.	1.7	10
4	The peptide hormone glucagon forms amyloid fibrils with two coexisting Î²-strand conformations. Nature Structural and Molecular Biology, 2019, 26, 592-598.	3.6	58
5	Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7344-7350.	1.0	28
6	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: Aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4328-4332.	1.0	16
7	Distinct Mutation Pathways of Non-Subtype B HIV-1 duringIn VitroResistance Selection with Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2010, 54, 4812-4824.	1.4	35
8	Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor. Antimicrobial Agents and Chemotherapy, 2009, 53, 2424-2431.	1.4	32
9	The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2959-2966.	1.0	56
10	Discovery of 3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses. Journal of Medicinal Chemistry, 2008, 51, 6503-6511.	2.9	120
11	The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2027-2030.	1.0	13
12	Design of Novel, Potent, Noncovalent Inhibitors of Thrombin with Nonbasic P-1 Substructures:Â Rapid Structureâ^'Activity Studies by Solid-Phase Synthesis. Journal of Medicinal Chemistry, 1998, 41, 1011-1013.	2.9	84
13	Synthesis of a Series of Potent and Orally Bioavailable Thrombin Inhibitors That Utilize 3,3-Disubstituted Propionic Acid Derivatives in the P3 Position. Journal of Medicinal Chemistry, 1997, 40, 3687-3693.	2.9	31
14	Design of Highly Potent Noncovalent Thrombin Inhibitors That Utilize a Novel Lipophilic Binding Pocket in the Thrombin Active Site. Journal of Medicinal Chemistry, 1997, 40, 830-832.	2.9	72